Gossamer Bio GOSS
Gossamer Bio reports $48.07 million net loss for Q3 2026
Gossamer Bio (GOSS) filed a 10-Q with the SEC on Nov 10, 2026, 4:49 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001728117-26-000114
- Revenue: $38.43 million for the three months ended Sep 30, 2026
- Net loss: $48.07 million for the three months ended Sep 30, 2026
- Diluted EPS: -$7.36 for the three months ended Sep 30, 2026
- Cash and equivalents: $51.19 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
Going-concern warning repeated
“Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern.”
Also in the prior 10-Q (filed Aug 13, 2026). Prior report Prior on EDGAR
Quoted from the filing.
What changed since last quarter
1 new risk factor · 1 new legal mention
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $38.43M | $9.24M | +316% |
| Operating income and margin | $7.2M · 18.7% | −$26.07M · -282.2% | +128%, margin +300.9 pts |
| Net income | −$48.07M | $16.9M | −384% |
| Operating cash flow | −$29.58M | −$39.42M | +25% |
| Cash | $51.19M | $41.15M | +24% |
New risk factors (1)
- We may not receive some or all of the additional proceeds contemplated by the Private Placement, which could adversely affect our liquidity and our ability to fund our operations. +2 more paragraphs
New legal mentions (1)
- On August 10, 2026, Lead Plaintiff and additional named plaintiffs Mike Fleming and Peter Zech, or collectively, Plaintiffs, filed an amended complaint against the Company, Faheem Hasnain, and Bryan Giraudo (collectively, "Defendants"). +4 more paragraphs